JLE

European Journal of Dermatology

MENU

Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins Volume 26, issue 2, March-April 2016

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
1 Department of Dermatology,
Kurume University School of Medicine,
and Kurume University Institute of Cutaneous Cell Biology,
67 Asahimachi, Kurume,
Fukuoka 830-0011,
Japan
2 Department of Maxillofacial Surgery,
Aichi-Gakuin University School of Dentistry,
Nagoya,
Aichi,
Japan
3 Antibody Engineering Department/Manufacturing Division
4 Clinical Development Department/Business Development Division
5 Marketing & Technical Support Department,
Medical & Biological Laboratories Co. LTD.,
Nagoya, Aichi,
Japan
6 Department of Dermatology,
St. Marianna University School of Medicine,
Kawasaki, Kanagawa,
Japan
* Reprints.

Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, affecting mainly elderly people [1], and shows IgG antibodies against the epidermal basement membrane zone (BMZ) [2]. BP is clinically characterized by itchy urticarial erythemas and tense blisters [3] and occasionally shows involvement of the oral mucous membrane [2]. Histopathology reveals subepidermal blisters with eosinophilic infiltration [4], and direct immunofluorescence (IF) reveals deposits of IgG and/or C3 to [...]